Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy

• Published in: Frontiers in immunology Vol. 13; p. 830220
• Main Authors: Lin, Enyu, Zhu, Ping, Ye, Chujin, Huang, ManLi, Liu, Xuechao, Tian, Kaiwen, Tang, Yanlin, Zeng, Jiayi, Cheng, Shouyu, Liu, Jiumin, Liu, Yanjun, Yu, Yuming
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.05.2022
• Subjects: Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - therapy; clear cell renal cell carcinoma (ccRCC); genomic alteration; Genomics; Humans; Immunology; Immunotherapy; Kidney Neoplasms - drug therapy; Kidney Neoplasms - therapy; multi-omics analysis; Prognosis; tumor immune microenvironment; Tumor Microenvironment - genetics; multi-omics analysis; clear cell renal cell carcinoma (ccRCC); genomic alteration; tumor immune microenvironment; immunotherapy
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.830220

Unlike early clear cell renal cell carcinoma (ccRCC), locally advanced and metastatic ccRCC present poor treatment outcomes and prognosis. As immune checkpoint inhibitors have achieved favorable results in the adjuvant treatment of metastatic ccRCC, we aimed to investigate the immunogenomic landscape during ccRCC progression and its potential impact on immunotherapy and prognosis. Using multi-omics and immunotherapy ccRCC datasets, an integrated analysis was performed to identify genomic alterations, immune microenvironment features, and related biological processes during ccRCC progression and evaluate their relevance to immunotherapy response and prognosis. We found that aggressive and metastatic ccRCC had higher proportions of genomic alterations, including SETD2 mutations, Del(14q), Del(9p), and higher immunosuppressive cellular and molecular infiltration levels. Of these, the Del(14q) might mediate immune escape in ccRCC via the VEGFA-VEGFR2 signaling pathway. Furthermore, immune-related pathways associated with ccRCC progression did not affect the immunotherapeutic response to ccRCC. Conversely, cell cycle pathways not only affected ccRCC progression and prognosis, but also were related to ccRCC immunotherapeutic response resistance. Overall, we described the immunogenomic characteristics of ccRCC progression and their correlations with immunotherapeutic response and prognosis, providing new insights into their prediction and the development of novel therapeutic strategies.